DEFA14A 1 ea02772491-defa14a_citius.htm DEFINITIVE ADDITIONAL MATERIALS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the Appropriate Box:

☐

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐

Definitive Proxy Statement

☒

Definitive Additional Materials

☐

Soliciting Material Under Rule 14a-12

Citius Pharmaceuticals, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒

No fee required.

☐

Fee paid previously with preliminary materials:

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V85101 - P47163 You invested in CITIUS PHARMACEUTICALS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on April 6, 2026. Get informed before you vote View the Proxy Statement and Annual Report on Form 10 - K online OR you can receive a free paper or email copy of the material(s) by requesting prior to March 23, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ 07016 CITIUS PHARMACEUTICALS, INC. 2026 Annual Meeting Vote by April 5, 2026 11:59 PM ET Vote in Person at the Meeting* April 6, 2026 8:00 AM, EST Company’s Headquarters 11 Commerce Drive, First Floor Cranford, New Jersey 07016

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V85102 - P47163 For 1. To elect seven directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Nominees: 1) Myron Holubiak 05) Dr. Eugene Holuka 2) Leonard Mazur 06) Dennis M. McGrath 3) Suren Dutia 07) Robert Smith 4) Carol Webb For 2. To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the fiscal year ending September 30, 2026. NOTE: To transact such other business as may properly come before the meeting or any adjournment thereof. Voting Items Board Recommends

SEC Form DEFA14A filed by Citius Pharmaceuticals Inc.